Advertisement

Search Results

Advertisement



Your search for Edith A. Perez, MD matches 32 pages

Showing 1 - 32


Susan G. Komen Welcomes Five Leaders to New Research Advisory Roles

Susan G. Komen recently announced new organizational advisory roles for five breast cancer oncologists. The new appointees will join the group of breast cancer researchers, clinicians, and advocates who help guide the organization’s work, particularly through the organization’s $988 million...

solid tumors
breast cancer

Adjuvant Pertuzumab in HER2-Positive Breast Cancer: Value Yet to Be Demonstrated

The ASCO Post issue of June 25, 2017, did an excellent job of summarizing the results and controversy generated by the initial results of the APHINITY trial, reported at the 2017 ASCO Annual Meeting and published simultaneously online in The New England Journal of Medicine.1 With a median follow-up ...

solid tumors
hematologic malignancies
breast cancer
lung cancer
prostate cancer
multiple myeloma
kidney cancer

Journal of Clinical Oncology Literature Update

Staying up-to-date in the fast-paced world of oncology literature is a daunting task at best. To assist with that task, The ASCO Post has assembled an assortment of studies recently published in the Journal of Clinical Oncology. The topics range from therapy for stage IV non–small cell lung cancer...

ASCO Honors Researchers, Scientists for Significant Advances in Cancer Treatment and Care

ASCO and the Conquer Cancer Foundation (CCF) proudly announce the winners of ASCO’s Special Awards, the Society’s highest honors, and the CCF Women Who Conquer Cancer Mentorship Award. The recipients of these awards include researchers, patient advocates, and global oncology leaders who have worked ...

ASCO Honors Researchers and Scientists for Significant Advancements in Cancer Treatment and Care

ASCO and the Conquer Cancer Foundation of ASCO (CCF) have proudly announced the winners of ASCO's Special Awards, the Society's highest honors, and the CCF Women Who Conquer Cancer Mentorship Award. The recipients of these awards include researchers, patient advocates, and global oncology leaders...

breast cancer

Assessment of Therapeutic Response by Intrinsic Subtype for HER2-Positive Breast Tumors

In an analysis of outcomes in the North Central Cancer Treatment Group/Alliance N9831 trial reported in the Journal of the National Cancer Institute, Edith A. Perez, MD, of the Mayo Clinic Cancer Center, and colleagues found that patients with tumors scored as HER2-enriched or luminal subtype...

breast cancer

Phase III Trial Shows Ado-Trastuzumab Emtansine Noninferior to Trastuzumab/Taxane in HER2-Positive Breast Cancer

In the phase III MARIANNE trial reported in the Journal of Clinical Oncology, Perez et al found that ado-trastuzumab emtansine (formerly known as T-DM1; Kadcyla) was associated with noninferior progression-free survival compared with trastuzumab (Herceptin) plus taxane in patients with...

breast cancer

Edith A. Perez, MD, on Stromal Tumor-Infiltrating Lymphocytes in Early-Stage HER2-Positive Breast Cancer

Edith A. Perez, MD, of the Mayo Clinic Cancer Center, discusses abstract S1-06, “Stromal tumor-infiltrating lymphocytes: In the Alliance N9831 trial S-TILs are associated with chemotherapy benefit but not associated with trastuzumab benefit.”

breast cancer

William J. Gradishar, MD, and Edith A. Perez, MD, on Immunotherapy and highlights of the Bolero-1 and SOFT Trials

William J. Gradishar, MD, of Northwestern University, and Edith A. Perez of the Mayo Clinic Cancer Center, discuss immunotherapy and the highlights of the BOLERO-1 and SOFT trials.

breast cancer

Optimizing HER2-directed Therapy in the Clinic

Seminal research in the treatment of HER2-positive breast cancer has been led by Edith A. Perez, MD, the Serene M. and Frances C. Durling Professor of Medicine at the Mayo Clinic, Jacksonville, Florida. The ASCO Post asked Dr. Perez to share her approach to HER2-directed therapy. Testing...

breast cancer

Single-agent Lapatinib Arm Discontinued in ALTTO

The Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization (ALTTO) study, which is evaluating various anti-HER2 therapy approaches in breast cancer, has discontinued the single-agent lapatinib (Tykerb) arm, according to study sponsor GlaxoSmithKline. Following a preplanned interim analysis...

SIDEBAR: Notes from the Lead Investigator 

We conducted this study to clarify a hypothesis that had been generated from preclinical work and small clinical datasets. One additional background point that should be made is that although not all previously reported small datasets had demonstrated a relationship between PTEN expression and...

breast cancer

Outcomes with Adjuvant Trastuzumab in HER2-positive Breast Cancer Not Affected by PTEN Status 

PTEN is a negative regulator of PI3K/AKT signaling. PI3K/AKT signaling can be activated by HER2, and it has been hypothesized that alteration in this pathway may affect sensitivity to trastuzumab (Herceptin). Preclinical data and some of the limited available clinical data suggest that loss or...

Expert Point of View: Edith A. Perez, MD

The PrefHer trial provides notable data showing that > 90% of patients favored the quicker subcutaneous administration of trastuzumab (Herceptin) compared to the standard intravenous infusion. The primary reasons for this preference, as per patients in the trial, included that it was timesaving...

Expert Point of View: Edith Perez, MD

Commenting on the I-SPY 2 neratinib results presented at the 2014 American Association for Cancer Research Annual Meeting, Edith Perez, MD, Deputy Director at Large, Mayo Clinic Comprehensive Cancer Center, Jacksonville, Florida, said that results were consistent with other data. “Testing for HER2...

breast cancer

ALTTO Trial Finds Dual Anti-HER2 Therapy No Better Than Trastuzumab Alone

The highly anticipated results from the phase III ALTTO trial show no additional benefit for adding lapatinib (Tykerb) to trastuzumab (Herceptin) in the adjuvant treatment of HER2-positive breast cancer.1 The results were presented at the 2014 ASCO Annual Meeting’s Plenary Session by Martine J....

breast cancer

Immune-Related Genes Predictive of Trastuzumab Benefit

Improved relapse-free survival following treatment with adjuvant trastuzumab (Herceptin) appears to be associated with a heightened state of immunologic function, according to genomic analysis that resulted in a 14-gene profile predictive of outcomes in the landmark NCCTG (Alliance) N9831 trial.1...

breast cancer

Joint Analysis Further Confirms Well-Established Standard of Care in Early Breast Cancer

This analysis demonstrates excellent news related to the long-term benefit of adding 1 year of trastuzumab (Herceptin) starting with the paclitaxel portion of adjuvant chemotherapy for patients with resected HER2-positive breast cancer. The study reflects the fact that excellent science in...

breast cancer

Long-Term Overall Survival Benefit Seen With Trastuzumab Added to Adjuvant Chemotherapy in Early-Stage HER2-Positive Breast Cancer

Earlier planned joint analyses of outcomes in the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-31 trial and the North Central Cancer Treatment Group (NCCTG) N9831 trial showed that adding trastuzumab (Herceptin) to adjuvant chemotherapy improved disease-free survival and overall...

breast cancer

News Roundup From the 2014 San Antonio Breast Cancer Symposium

Highlighted here are summaries of four abstracts presented at the 2014 San Antonio Breast Cancer Symposium: They focus on the EPO-ANE-3010 clinical trial of epoetin alfa (Epogen, Procrit) in anemic patients with metastatic breast cancer, a New York Cancer Consortium trial of fulvestrant (Faslodex)...

breast cancer

SOFT Trial Results Inconclusive: Further Study Needed

The results of the SOFT trial—presented at the 2014 San Antonio Breast Cancer Symposium, reported recently by Francis et al in The New England Journal of Medicine,1 and reviewed in this issue of The ASCO Post—were not as conclusive as we had hoped. In essence, the study enrolled women with resected ...

breast cancer

Adjuvant Ovarian Suppression May Benefit Women With Premenopausal Breast Cancer Who Received Prior Chemotherapy

In a phase III trial (SOFT) reported in The New England Journal of Medicine, Prudence A. Francis, MD, of Peter MacCallum Cancer Centre, Melbourne, Australia, Meredith M. Regan, ScD, of IBCSG Statistical Centre at Dana-Farber Cancer Institute, Boston, and colleagues found that the addition of...

American Association for Cancer Research Elects New Board of Directors, Nominating Committee Members

The members of the American Association for Cancer Research (AACR) have elected five members to serve on the AACR board of directors for the 2015–2018 term and four members to serve on the nominating committee for the 2015–2017 term. They will begin their terms at the AACR Annual Meeting 2015, to...

breast cancer

Immune Gene Profile Strongly Associated With Benefit of Adjuvant Trastuzumab in HER2-Positive Breast Cancer

In a study reported in the Journal of Clinical Oncology, Edith A. Perez, MD, of the Mayo Clinic, Jacksonville, and colleagues found that an immune function gene profile was associated with significantly improved relapse-free survival among patients with early-stage HER2-positive breast cancer who...

breast cancer

Studies Explore New Avenues to Pursue in Metastatic Triple-Negative Breast Cancer

Two agents targeting novel pathways show promise in metastatic triple-negative breast cancer, according to separate studies presented at the 2015 ASCO Annual Meeting and reviewed at the Best of ASCO® meeting by Steven J. Isakoff, MD, PhD, of Massachusetts General Hospital, Boston. The first study...

breast cancer

Mayo Clinic Receives Federal Grant to Fund Clinical Test of Triple-Negative Breast Cancer Vaccine

Researchers on Mayo Clinic’s Florida campus have been awarded a $13.3 million, 5-year federal grant to test a vaccine designed to prevent the recurrence of triple-negative breast cancer. This Breakthrough Award from the U.S. Department of Defense’s Breast Cancer Research Program will fund a...

breast cancer

No Significant Survival Improvement With Etirinotecan Pegol vs Physician’s Choice in Heavily Pretreated Advanced Breast Cancer

In the phase III BEACON trial reported in The Lancet Oncology, Perez et al found that etirinotecan pegol was not associated with a significant increase in overall survival compared with physician’s choice of treatment in women with locally recurrent or metastatic breast cancer previously...

breast cancer

6-Year Incidence of Cardiac Events in NCCTG N9831/Alliance Adjuvant Trastuzumab Trial

As reported in the Journal of Clinical Oncology by Advani et al, the cumulative incidence of cardiac events remained significantly higher at 6 years in breast cancer patients who received adjuvant trastuzumab (Herceptin) in the NCCTG N9831/Alliance trial. However, few new congestive heart failure...

breast cancer
issues in oncology

Immune Gene Profile Strongly Associated With Benefit of Adjuvant Trastuzumab in HER2-Positive Breast Cancer

In a study reported in the Journal of Clinical Oncology, Perez et al found that an immune function gene profile was associated with significantly improved relapse-free survival among patients with early-stage HER2-positive breast cancer who had trastuzumab (Herceptin) added to adjuvant chemotherapy ...

breast cancer

SABCS 2014: High Tumor Immune Cell Levels May Identify HER2-Positive Breast Cancer Patients Who Might Benefit From Chemotherapy Alone

Women with HER2-positive breast cancer who had high levels of immune cells in their tumors had a decreased risk of cancer recurrence after treatment with chemotherapy alone compared with their counterparts who had low levels of tumor-infiltrating immune cells, according to data presented at the...

breast cancer

Long-Term Overall Survival Benefit of Adding Trastuzumab to Adjuvant Chemotherapy in Early-Stage HER2-Positive Breast Cancer

Earlier planned joint analyses of outcomes in the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-31 trial and North Central Cancer Treatment Group (NCCTG) N9831 trial showed that adding trastuzumab (Herceptin) to adjuvant chemotherapy improved disease-free survival and overall...

breast cancer

ASCO 2014: Adding Lapatinib to Adjuvant Trastuzumab Does Not Improve Outcomes in Early-Stage HER2-Positive Breast Cancer

A large phase III study, ALTTO (Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation), found no statistically significant differences in 4-year disease-free survival among women with early HER2-positive breast cancer who received adjuvant treatment that combined the HER2-targeted drugs...

Advertisement

Advertisement



;
Advertisement